Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 15/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 15/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TYMP | P19971 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3965261 | 0.83 | DRD2 (0.50) | DRD2DRD4DRD3SLC6A4HTT | |
| SCHEMBL13801363 | 0.83 | DRD2 (0.50) | DRD2DRD4DRD3SLC6A4SLC6A3 | |
| SCHEMBL14410230 | 0.82 | DRD2 (0.46) | DRD2DRD4DRD3SLC6A2SLC6A4 | |
| SCHEMBL14098821 | 0.82 | DRD2 (0.46) | DRD2DRD4DRD3KDM4EMEN1 | |
| SCHEMBL3958053 | 0.81 | DRD2 (0.47) | DRD2DRD4DRD3SLC6A2SLC6A4 | |
| SCHEMBL3962522 | 0.80 | DRD2 (0.61) | DRD2DRD4DRD3 | |
| SCHEMBL17803212 | 0.80 | DRD2 (0.48) | DRD2DRD4DRD3KDM4EMEN1 | |
| SCHEMBL3253448 | 0.80 | DRD2 (0.48) | DRD2DRD4DRD3KDM4EMEN1 | |
| SCHEMBL3247769 | 0.80 | DRD2 (0.48) | DRD2DRD4DRD3 | |
| SCHEMBL2102005 | 0.79 | DRD2 (0.64) | DRD2DRD4DRD3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7407963-B2 | Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-08-05 | — | — | US | disclosed |
| EP-1440976-B1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-07-23 | — | — | EP | disclosed |
| US-7230001-B1 | Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-20040214819-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2004-10-28 | — | — | US | disclosed |
| EP-1440976-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-07-28 | — | — | EP | disclosed |
| EP-0927192-B1 | MODIFIED AMINOACIDS, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND METHOD FOR THEIR PRODUCTION | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-05-12 | — | — | EP | disclosed |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2003-04-10 | — | — | US | disclosed |
| US-6344449-B1 | HEADACHE AND MORPHINE DEPENDENCE | DR. KARL THOMAE GMBH (DE) | 2002-02-05 | — | — | US | disclosed |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2001-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | DRD2 187/4885DRD4 139/4885DRD3 160/4885 |
| US-20040214819-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, SRMS, OPRM1 | DRD2 198/4885DRD4 125/4885DRD3 168/4885 |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | SLC1A5, NEFM, SRMS | DRD2 130/4885DRD4 86/4885DRD3 106/4885 |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, SRMS, OPRM1 | DRD2 198/4885DRD4 125/4885DRD3 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.